SCHEMBL8326663

SCHEMBL8326663

COC[C@H]1CCCN1C(=O)c1cc2ncnc(NC(C)c3nc4cc(Cl)ccc4[nH]3)c2cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.45
DPP4 P27487 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
DPP9 Q86TI2 1/20 0.38
BCL6 P41182 1/20 0.38
LRRK2 Q5S007 2/20 0.36
USP1 O94782 3/20 0.36
TLR8 Q9NR97 2/20 0.35
TLR7 Q9NYK1 2/20 0.35
TLR9 Q9NR96 1/20 0.35
EGFR P00533 7/20 0.35
ERBB2 P04626 5/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PDE7B Q9NP56 1/20 0.35
DHODH Q02127 1/20 0.35
HDAC3 O15379 2/20 0.34
HDAC4 P56524 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4156701 1.00 SOS1 (0.45) SOS1DPP4DPP8DPP9BCL6
SCHEMBL4158137 1.00 SOS1 (0.45) SOS1DPP4DPP8DPP9BCL6
SCHEMBL4158134 1.00 SOS1 (0.45) SOS1DPP4DPP8DPP9BCL6
SCHEMBL4156698 1.00 SOS1 (0.45) SOS1DPP4DPP8DPP9BCL6
SCHEMBL8325057 1.00 SOS1 (0.45) SOS1DPP4DPP8DPP9BCL6
SCHEMBL4148970 0.92 SOS1 (0.37) SOS1USP1TLR8TLR7TLR9
SCHEMBL13772349 0.92 SOS1 (0.37) SOS1USP1TLR8TLR7TLR9
SCHEMBL3004192 0.92 SOS1 (0.37) SOS1EGFRKDM4EALDH1A1LMNA
SCHEMBL4158303 0.92 SOS1 (0.37) SOS1USP1TLR8TLR7TLR9
SCHEMBL8321571 0.92 SOS1 (0.37) SOS1USP1TLR8TLR7TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-07-16 US disclosed
US-7429597-B2 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-09-30 US disclosed
US-7429597-B2 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-09-30 US disclosed
WO-2004058743-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS F12, F11, F2 SOS1 1153/4885DPP4 3971/4885DPP8 4122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.